What is LetsGetChecked?
LetsGetChecked operates as a sophisticated medical technology platform designed to streamline the delivery of diagnostic services. By providing a seamless interface between customers and a comprehensive network of global laboratories, the company facilitates personal at-home health testing with clinical precision. Headquartered in New York, the firm has effectively disrupted traditional diagnostic pathways, offering a scalable solution that empowers individuals to manage their health outcomes through data-driven insights. Its market position is defined by its integration of logistics, digital health connectivity, and high-throughput laboratory partnerships, making it a critical player in the modern healthcare ecosystem.
How much funding has LetsGetChecked raised?
LetsGetChecked has raised a total of $263M across 4 funding rounds:
Series A
$12M
Series C
$71M
Series B
$30M
Series D
$150M
Series A (2018): $12M with participation from Optum Ventures
Series B (2020): $30M, investors not publicly disclosed
Series C (2020): $71M supported by Deerfield, CommonFund Capital, Transformation Capital, Angeles Investments, Optum Ventures, HLM Venture Partners, Qiming Venture Partners USA, and Illumina Ventures
Series D (2021): $150M featuring Casdin Capital
Key Investors in LetsGetChecked
Casdin Capital
Casdin Capital is a specialized investment firm founded in 2011 that focuses on financing the next generation of life science innovation, with deep expertise in diagnostics and molecular information.
Optum Ventures
Optum Ventures is a strategic investment arm dedicated to improving healthcare by backing early-stage companies that are poised to disrupt the status quo.
Deerfield Management
Deerfield Management is an investment firm focused on advancing healthcare through a combination of capital, intelligence, and philanthropy, supporting innovation across the entire healthcare ecosystem.
What's next for LetsGetChecked?
With the support of its latest financing, LetsGetChecked is well-positioned to accelerate its product roadmap and expand its diagnostic service offerings. The company is expected to leverage this capital to enhance its laboratory infrastructure, invest in proprietary technology to improve user experience, and potentially explore new therapeutic areas within the precision health market. As the demand for remote health monitoring continues to rise, the firm's strategic focus will likely remain on scaling its operational capacity while maintaining the rigorous clinical standards required for high-stakes diagnostic testing. This growth phase will be pivotal in determining the company's long-term influence on the future of personalized medicine.
See full LetsGetChecked company page